Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use

• US 5,866,603 A
• Filed: 06/07/1995
• Issued: 02/02/1999
• Est. Priority Date: 11/17/1994
• Status: Expired due to Fees

• Current Assignee: Duquesne University of The Holy Ghost
• Original Assignee: Duquesne University of The Holy Ghost
• Inventors: Li, Pui-Kai, Selcer, Kyle W.
• Primary Examiner(s): PRIOR, KIMBERLY
• Application Number:
  US08/476,360
• Time in Patent Office: 1,336 Days
• Field of Search: 552/521
• US Class Current: 514/303
• CPC Class Codes: C07J 41/0005 the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton

Abstract

This invention discloses compounds useful as steroid sulfatase inhibitors. The compounds comprise the formula (1) ##STR1## wherein (a) R is selected from the group consisting of hydrogen, a lower alkyl group, an alkoxy group, halogen, NH₂, NO₂, C.tbd.N and N═C═S; and (b) the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiols, estradiolesters, pregnenolone, substituted estrones, substituted dehydroepiandrosterones, substituted estradiols, substituted estradiolesters and substituted pregnenolone. The compounds also comprise the formula (5) ##STR2## wherein (a) R₁ is hydrogen and R₂ is selected from the group consisting of SO₂ CF₃, SO₂ NH₂, SO₂ (C₁ -C₆ -alkyl), COCF₃, CONH₂, CO(C₁ -C₆ -alkyl); and (b) the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiol, estradiolester, pregnenolone, substituted estrones, substituted dehydroepiandrosterone, substituted estradiols, substituted estradiolesters and substituted pregnenolone. The invention also discloses methods of treating a patient therapeutically and prophylactically for estrogen dependent diseases with the compounds of this invention.

Claims

1. A compound comprising the formula (1) ##STR29## wherein (a) R is selected from the group consisting of hydrogen, a lower alkyl group, an alkoxy group, halogen, NH₂, NO₂, C.tbd.N, and N═

C═

S and (b) the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiols, estradiolesters, pregnenolone, substituted estrones, substituted dehydroepiandrosterones, substituted estradiols, substituted estradiolesters and substituted pregnenolone.

2. The compound of claim 1, wherein said lower alkyl group has one to six carbon atoms, wherein said alkoxy group has one to four carbon atoms and wherein said halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine.

3. The compounds of claim 1 comprising the species formula (2) ##STR30## wherein R is selected from the group consisting of hydrogen, a lower alkyl group of one to six carbon atoms, an alkoxy group of one to four carbon atoms, NH₂, NO₂, C.tbd.N, N═

C═

S and a halogen selected from the group consisting of F, Cl, Br and I.

4. The compound of claim 3 wherein R is hydrogen.

5. The compound of claim 3 wherein R is 4-methyl.

6. The compound of claim 3 wherein R is 4-methoxy.

7. The compound of claim 3 wherein R is a nitro selected from the group consisting of 2-NO₂, 3-NO₂ and 4-NO₂.

8. The compound of claim 3 wherein R is a halogen selected from the group consisting of 4-fluoro, 4-chloro, 4-bromo, 4-iodo.

9. The compound of claim 3 wherein R is selected from the group consisting of 2-NH₂ and 3-NH₂ and 4-NH₂.

10. The compounds of claim 1 comprising the species formula (3) ##STR31## wherein R is selected from the group consisting of hydrogen, a lower alkyl group of one to six carbon atoms, an alkoxy group of one to four carbon atoms, NH₂, NO₂, C.tbd.N, N═

C═

S and a halogen selected from the group consisting of F, Cl, Br and I.

11. The compound of claim 10 wherein R is Hydrogen.

12. The compound of claim 10 wherein R is 4-methoxy.

13. The compound of claim 10 wherein R is a nitro selected from the group consisting of 2-NO₂ 3-NO₂ and 4-NO₂.

14. The compound of claim 10 wherein R is a halogen selected from the group consisting of 4-fluoro, 4-chloro, 4-bromo, 4-iodo.

15. The compound of claim 10 wherein R is selected from the group consisting of 2-NH₂ and 3-NH₂ and 4-NH₂.

16. The compounds of claim 1 comprising the species formula (4) ##STR32## wherein R is selected from the group consisting of hydrogen, a lower alkyl group of one to six carbon atoms, an alkoxy group of one to four carbon atoms, NH₂, NO₂, C.tbd.N, N═

C═

S and a halogen selected from the group consisting of F, Cl, Br and I.

17. The compound of claim 16 wherein R is hydrogen.

18. The compound of claim 16 wherein R is 4-methoxy.

19. The compound of claim 16 wherein R is a nitro selected from the group consisting of 2-NO₂, 3-NO₂ and 4-NO₂.

20. The compound of claim 16 wherein R is a halogen selected from the group consisting of 4-fluoro, 4-chloro, 4-bromo, 4-iodo.

21. The compound of claim 16 wherein R is selected from the group consisting of 2-NH₂, 3-NH₂ and 4-NH₂.

22. A method of therapeutically treating a patient comprising providing a compound having the formula (1) ##STR33## wherein R is selected from the group consisting of hydrogen, a lower alkyl group, an alkoxy, halogen, NH₂, NO₂, C.tbd.N and N═

C═

S and the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiols, estradiolesters, pregnenolone, substituted estrones, substituted dehydroepiandrosterones, substituted estradiols, substituted estradiolesters and substituted pregnenolone,

incorporating said compound in a suitable pharmaceutical carrier;

administering a therapeutically effective dosage of said compound incorporated in said carrier to said patient; and

employing said method in therapeutically treating a patient for estrogen related diseases selected from the group consisting of breast cancer, ovarian cancer, vaginal cancer, endometrial cancer and endometriosis.

23. The method of claim 22, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose.

24. The method of claim 23, including administering said compound incorporated in said carrier to a patient by the parenteral route.

25. The method of claim 23, including administering said compound incorporated in said carrier to a patient by the oral route.

26. The method of therapeutically treating a patient of claim 22 employing a compound having the species formula (2) ##STR34## wherein R is selected from the group consisting of hydrogen, a lower alkyl group of one to six carbon atoms, a alkoxy group of one to four carbon atoms, NH₂, NO₂, C.tbd.N, N═

C═

S and a halogen selected from the group consisting of F, Cl, Br and I.

27. The method of claim 26, including employing as said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

28. The method of claim 27, including administering said compound by injection into a patient.

29. The method of claim 27, including administering said compound incorporated in said carrier to a patient by the parenteral route.

30. The method of claim 27, including administering said compound incorporated in said carrier to a patient by the oral route.

31. The method of therapeutically treating a patient of claim 22 employing a compound having the species formula (3) ##STR35## wherein R is selected from the group consisting of hydrogen, a lower alkyl group of one to six carbon atoms, an alkoxy group of one to four carbon atoms, NH₂, NO₂, C.tbd.N, N═

C═

S and a halogen selected from the group consisting of F, Cl, Br and I.

32. The method of claim 31, including employing as sad carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

33. The method of claim 32, including administering said compound to a patient by injection.

34. The method of claim 32, including employing said carrier to said patient by the parenteral route.

35. The method of claim 32, including administering said compound incorporated in said carrier to said patient by the oral route.

36. The method of therapeutically treating a patient of claim 22 employing a compound having the species formula (4) ##STR36## wherein R is selected from the group consisting of hydrogen, a lower alkyl group of one to six carbon atoms, an alkoxy group of one to four carbon atoms, NH₂, NO₂, C.tbd.N, N═

C═

S and a halogen selected from the group consisting of F, Cl, Br and I.

37. The method of claim 36, including employing said carrier a solution selected from the group consisting of physiologic saline and 5% dextrose in water.

38. The method of claim 37, including administrating said compound in said carrier by injection.

39. The method of claim 37, including employing said carrier to a patient by the parenteral route.

40. The method of claim 37, including administering said compound incorporated in said carrier to a patient by the oral route.